

1 **Evaluation of commercial anti-SARS-CoV-2 antibody assays and comparison of**
2 **standardized titers in vaccinated healthcare workers.**

3

4 Kahina Saker¹, Vanessa Escuret^{1,4}, Virginie Pitiot², Amélie Massardier-Pilonchéry², Stéphane
5 Paul³, Bouchra Mokdad¹, Carole Langlois-Jacques⁵, Muriel Rabilloud⁵, David Goncalves⁶,
6 Nicole Fabien⁶, Nicolas Guibert², Jean-Baptiste Fassier², Antonin Bal¹, Sophie Trouillet-
7 Assant^{1,4}, Mary-Anne Trabaud¹.

8

9 ¹Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre
10 National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, IAI,
11 Centre de Biologie Nord, Groupement Hospitalier Nord, F-69317, Lyon Cedex 04, France

12 ²Occupational Health and Medicine Department, Hospices Civils de Lyon, Lyon, France

13 ³Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064,
14 University Hospital of Saint-Etienne, F-42055, Saint-Etienne cedex 2, France

15 ⁴CIRI- International Center of Research in Infectiology, INSERM U1111, CNRS UMR5308,
16 ENS Lyon, Claude Bernard Lyon 1 University, F-69008, Lyon, France.

17 ⁵CNRS, UMR 5558, University of Lyon, Laboratoire de Biométrie et Biologie Evolutive,
18 Equipe Biostatistique-Santé, F-69100, Villeurbanne, France

19 ⁶Immunology Department, Lyon Sud Hospital, Hospices Civils de Lyon, F69495, Pierre-
20 Bénite cedex, France

21 **Corresponding author**

22 Mary-Anne Trabaud, mary-anne.trabaud01@chu-lyon.fr

23 **Running title:** Comparison of SARS-CoV-2 antibody titers after vaccination

24 **Keywords:** SARS-CoV-2 antibodies; quantification; commercial assays; standardized titers;
25 vaccination; health care workers

26 **Abstract**

27 With the availability of vaccines, commercial assays detecting anti-SARS-CoV-2 antibodies
28 (Ab) evolved towards quantitative assays directed to the spike glycoprotein or its receptor
29 binding domain (RBD). The main objective of the present study was to compare the Ab titers
30 obtained with quantitative commercial binding Ab assays, after 1 dose (convalescent
31 individuals) or 2 doses (naive individuals) of vaccine, in healthcare workers (HCW).

32 Antibody titers were measured in 263 sera (from 150 HCW) with 5 quantitative
33 immunoassays (Abbott RBD IgG II quant, bioMerieux RBD IgG, DiaSorin Trimeric spike
34 IgG, Siemens Healthineers RBD IgG, Wantai RBD IgG). One qualitative total antibody anti
35 RBD detection assay (Wantai) was used to detect previous infection before vaccination. The
36 results are presented in binding Ab units (BAU)/mL after application, when possible, of a
37 conversion factor provided by the manufacturers and established from a World Health
38 Organization (WHO) internal standard.

39 There was a 100% seroconversion with all assays evaluated after two doses of vaccine. With
40 assays allowing BAU/ml correction, Ab titers were correlated ($\rho= 0.84-0.99$). However, a
41 significant difference between values persisted. The titer differences varied by a mean 3.04%
42 between Siemens and bioMerieux assays to 50.54% between Siemens and DiaSorin assays.

43 Titer harmonization is still to be improved despite better results were obtained between assays
44 detecting the same Ab against the same antigen. The next step towards a true standardization
45 of the assays would be to include the International Standard in the calibration of each assays
46 to express the results in IU/mL.

47

48

49 **Introduction**

50 Since the end of 2020, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
51 vaccines have been developed and are now available worldwide with the aim of achieving
52 herd immunity to control the pandemic. Vaccine immunity involves both cellular and humoral
53 pathways. Cellular immunity is not easy to assess on a large scale, as is the neutralizing
54 humoral response owing to requirement for a biosafety level 3 (BSL3) containment
55 laboratory; the evaluation of vaccine effectiveness therefore mainly relies on high throughput
56 serological tests to assess individual humoral immunity as well as monitoring SARS-CoV-2
57 seroprevalence (1).

58 To consider binding antibodies (Ab) as a marker of vaccine effectiveness, several conditions
59 must be met. First, binding Ab assays should be quantitative; second, titers should be
60 consistent between different assays; third, binding Ab titers should correlate with neutralizing
61 Ab titers; fourth, the minimum binding Ab titer associated with virus neutralization must be
62 found; and fifth, the association between neutralizing Ab and vaccine protection must be
63 demonstrated. It can be considered that the first and fifth conditions have been met given that
64 commercial tests for the quantitative detection of binding Ab have been developed (2–7), and
65 that the role of neutralizing Ab in the infection protection have been demonstrated in animals
66 and humans (8–11); this is not the case for the other conditions. In particular, the second point
67 is of importance for widespread evaluation of vaccines, but until now Ab titers were often
68 expressed as an index or unit with regard to an internal standard that differs between
69 manufacturers. Recently, the World Health Organization (WHO) has developed an
70 international standard (12) against which each supplier can standardize their assay, allowing
71 comparability of titers between kits. The present study was conducted to evaluate the
72 performance of commercial antibody assays in detecting vaccination-associated anti-SARS-

73 CoV-2 Ab seroconversion; the main objective was to compare Ab titers from quantitative
74 assays after conversion of titers using the WHO standard.

75

76 **Materials and Methods**

77 **Antibody binding assays**

78 Six Ab binding assays were investigated according to the protocol recommended by each
79 manufacturer (the characteristics of the assays are summarized in Table 1). Five were
80 quantitative: Siemens Healthineers (Erlangen, Germany) Atellica® IM SARS-CoV-2 IgG
81 (sCOVG), DiaSorin (Saluggia, Italy) Liaison® SARS-CoV-2 TrimericS IgG, bioMérieux
82 (Marcy l'Etoile, France) Vidas® SARS-CoV-2 IgG, Abbott (Abbott park, IL, USA) Architect
83 SARS-CoV2 IgG II Quant, and Wantai (Beijing, China) SARS-CoV-2 IgG assays. The
84 Wantai SARS-CoV-2 total antibody assay is qualitative and was selected to detect a previous
85 infection before vaccination based on its better sensitivity previously shown in infected
86 individuals (13). The First International Standard developed by the WHO (National Institute
87 for Biological Standards and Control code: 20/136) corresponds to lyophilized pooled plasma
88 from patients who had been infected with SARS-CoV-2; after reconstitution, the solution
89 contains 1000 binding antibody units (BAU) per mL (12). For conversion of titers obtained
90 using the quantitative assays, the concentrations expressed in arbitrary units per mL, or index
91 according to the assay, (Table 1) were converted to BAU/mL using the conversion factors
92 provided by the manufacturer (with the exception of the Wantai SARS-CoV-2 IgG assay for
93 which the conversion factor was not available and presented here only to compare the
94 positivity rate between assays); these were 21.8 for the Siemens assay, 2.6 for the DiaSorin
95 assay, 20.33 for the bioMérieux assay, and 0.142 for the Abbott assay (considering that 1
96 BAU/mL = conversion factor x AU/mL or index). Samples with results above the upper limit
97 of quantification were tested again after dilution (1/5 when above 3270 BAU/mL for the

98 Siemens assay, 1/20 when above 2080 BAU/mL for the DiaSorin assay, and 1/20 when above
99 18 index for the bioMérieux assay).

100

101 **Samples from the study population**

102 A prospective longitudinal cohort study was conducted at the laboratory associated with the
103 national reference center for respiratory viruses (University Hospital of Lyon, France).

104 Healthcare workers, excluding pregnant women (HCW; n=150) who were scheduled to
105 receive 2 doses of Pfizer BioNtech vaccine (n=94; BNT162b2/BNT162b2) or 1 dose of

106 AstraZeneca vaccine followed by 1 dose of Pfizer BioNtech vaccine (n=56;
107 ChAdOx1/BNT162b2) were included. Blood samples were collected i) before the first dose of

108 vaccine, ii) before the second injection of vaccine corresponding to 4 weeks after the first
109 dose for participants vaccinated with 2 doses of Pfizer BioNtech vaccine or 12 weeks for

110 those vaccinated with the AstraZeneca vaccine, and iii) 4 weeks after the full vaccination. The
111 pre-vaccination blood sample was only used to document a previous SARS-CoV-2 infection.

112 Among the participants 26 who were previously infected with SARS-CoV-2 (convalescent
113 group; 17.4%) had only one vaccine injection (Pfizer BioNtech, n=15 or Astra Zeneca, n=11);

114 for these the second sample was omitted. Three participants were infected with SARS-CoV-2
115 between the 2 doses. Sera were immediately stored at -80°C after blood sampling.

116 Written informed consent was obtained from all participants; ethics approval was obtained
117 from the regional review board for biomedical research in April 2020 (*Comité de Protection*

118 *des Personnes Sud Méditerranée I*, Marseille, France; ID RCB 2020-A00932-37), and the
119 study was registered on ClinicalTrials.gov (NCT04341142).

120 **Samples for specificity assessment**

121 Specificity was assessed from 39 pre-pandemic sera specimens, collected between 2017 and
122 2019. These pre-pandemic sera were positive for antinuclear Ab (n=10), rheumatoid factor

123 (n=10), autoAb found in patients suffering from Crohn's disease (n=10), or for anti-
124 mycoplasma Ab (IgM; n=9). The 39 pre-pandemic sera specimens were tested with the
125 Wantai total Ab and bioMérieux IgG assays; due to insufficient volume, only 20 of them
126 could be tested with the Siemens and DiaSorin IgG assays.

127 **Statistical analyses**

128 Results were expressed by the median and interquartile range [IQR]. Paired comparison
129 between assays was performed using the Wilcoxon test. The correlation between
130 concentrations obtained by each assay was investigated using Pearson correlation coefficients
131 and 95% confidence interval (CI). The Bland-Altman method was used to measure the mean
132 difference and 95% limit of agreement between log-transformed concentrations obtained with
133 each assay. Statistical analyses were conducted using GraphPad Prism® software (version 8;
134 GraphPad software, La Jolla, CA, USA). A p-value <0.05 was considered statistically
135 significant.

136

137 **Results**

138 In the first part of the study, the performances of the 6 assays were compared to verify
139 whether the ability to detect anti-SARS-CoV-2 antibodies of the Wantai total Ab assay, which
140 is known to be the most sensitive post infection (13), was similar after vaccination, and
141 whether the sensitivity of qualitative and quantitative assays were also similar. The sera
142 collected from patients scheduled to receive only Pfizer BioNtech vaccine (n=94) were used
143 for this evaluation. Four weeks after the first injection, the proportion of positive samples was
144 over 90% for all assays except the Wantai assay detecting total antibodies (86.1%). Four
145 weeks after the second injection anti SARS CoV-2 antibodies were detected for all
146 participants with all the assays (Table 1). All assays were negative on pre-pandemic samples
147 from patients with autoantibodies or mycoplasma infection (100% specificity).

148 The second part of this study was to compare Ab titers after BAU/mL conversion; for this,
149 only the assays adapted or developed for the quantification of Ab induced by vaccine were
150 tested. The Siemens, DiaSorin and bioMérieux assays were compared using sera samples
151 collected before the second injection of vaccine and those collected after full vaccination, and
152 for which assays gave a positive quantitative result (263 samples). The median [IQR] values
153 obtained were 708.3 [90.47; 2439] BAU/mL for the Siemens assay, 1220 [241.8; 3370]
154 BAU/mL for DiaSorin, and 906.7 [128.1; 2289] BAU/mL for bioMérieux assays; there was a
155 significant difference in titers between DiaSorin and Siemens ($p < 0.0001$), as well as DiaSorin
156 and bioMérieux ($p < 0.0001$) assays. The difference in median titers between Siemens and
157 bioMérieux assays was not significant (Figure 1A). There was a strong correlation between
158 assays; the Pearson correlation coefficient (ρ [95%CI]) was 0.94 [0.92; 0.95] between
159 DiaSorin and Siemens assays, 0.86 [0.82; 0.89] between DiaSorin and bioMérieux assays, and
160 0.84 [0.80; 0.87] between Siemens and bioMérieux assays (Figure 2A, B, C).

161 According to the Bland-Altman method (Figure 3) there was a mean difference in titers
162 expressed as BAU concentrations of 3.04% [-72.37%; 78.38%] between the Siemens and
163 bioMérieux assays, 47.39% [-127.36%; 32.57%] between DiaSorin and bioMérieux, and
164 50.54% [-27.26%; 128.33%] between DiaSorin and Siemens assays.

165 There were 77 samples from HCW scheduled to receive only Pfizer BioNtech vaccine (68
166 after the first dose and 9 after the second dose) tested using the Abbott assay. The median
167 [IQR] values obtained were 114.5 [55.38; 382.2] BAU/mL for the Siemens assay, 116.3
168 [51.19; 295.7] for the Abbott assay, 169.1 [80.71; 384.5] for the bioMérieux assay, and 325
169 [131.8; 811.2] for the DiaSorin assay. The titers were significantly different between Abbott
170 and each other assay ($p < 0.0001$; Figure 1B), but the data from these assays were strongly
171 correlated; the Pearson correlation coefficient (ρ [95%CI]) was 0.99 [0.98; 0.99] between

172 Abbott and Siemens assays, 0.98 [0.96; 0.98] between Abbott and DiaSorin assays, and 0.99
173 [0.99; 0.997] between Abbott and bioMérieux assays (Figure 2D, E, F).

174

175

176 **Discussion**

177 In the present cohort of vaccinated HCW, the performance of first generation serological
178 assays, developed for diagnosis purpose, as well as second generation ones, adapted or
179 developed in order to assess the vaccine humoral response, were similar. However, first
180 generation assays are not useful to monitor vaccination effectiveness since they are not
181 quantitative or could not be compared to others. The more important finding of the present
182 study was that the quantitative assays, whose results could be standardized to BAU/ml,
183 produce results that are correlated to each other. The Ab titers obtained with the DiaSorin
184 assay, although correlated with those of the others assays, remained higher after conversion
185 using the WHO standard. This may be related to difference in the antigens targeted, as the
186 DiaSorin assay is the only one evaluated in this study, to use the trimeric spike protein (2).
187 The WHO standard was obtained from the plasma of convalescent patients (12) and must
188 therefore contain antibodies against numerous epitopes, thus the DiaSorin assay is probably
189 capable of reacting with more antibodies than assays detecting only antibodies specific for
190 RBD.

191 There are currently very few reports that have examined Ab binding assays with the use of the
192 WHO standard (3, 7). Perkman et al. (7) compared 4 assays detecting binding Ab, including
193 the Liaison anti SARS-CoV-2 trimericS IgG from DiaSorin and the Architect anti SARS-
194 CoV-2 RBD IgG from Abbott, used in the present study. In vaccinated individuals, after the
195 first dose of vaccine, titers varied significantly between the assays, but they indicated that the
196 recalculation in BAU/ml with the conversion factor given by the manufacturer did not solve

197 error problems between tests. However, the assays compared were more different in their
198 format than those investigated herein: total anti-RBD Ig versus anti-RBD IgG, anti-
199 monomeric spike IgG or anti-trimeric spike IgG. Interestingly, comparison of Abbott and
200 DiaSorin assays found, as was the case herein, higher titers for the DiaSorin assay. Later,
201 Bradley et al. (3) performed linear regressions from sample dilutions of the WHO standard to
202 determine a detection limit in international units (IU) per ml for each test; the authors
203 confirmed the linearity of the Abbott anti-SARS-CoV-2 IgG II Quant assay over the
204 analytical measurement interval but the conversion factor found seemed to be higher than
205 indicated by the manufacturer (1 IU/ml gave 6,1 arbitrary units/ml while Abbott indicated that
206 1 IU correspond to 7.1 arbitrary units). Taken together, these data suggest that there are
207 remaining differences between assays after conversion in BAU/ml and that this could be due
208 to the incorrect adjustment of the correction factor by the manufacturers. The next step for a
209 true harmonization would therefore be to use the international standard to calibrate each assay
210 instead of applying a conversion factor to a result obtained with an assay previously calibrated
211 with an internal standard (14).

212 A limitation of this study is that the specificity analysis was limited to a small group of
213 patients with auto-immune diseases or mycoplasma infection. However, assay specificity
214 analyses have been performed by manufacturers and independent groups (2, 4–6) showing
215 specificity $\geq 99\%$ for all the quantitative assays. In addition, not all commercial quantitative
216 anti-SARS-CoV-2 Ab assays were evaluated limiting the scope of the conclusions.
217 Furthermore, neutralizing Ab were not investigated that could have helped determine whether
218 anti-RBD or anti-spike assays are the most correlated with virus neutralization. However,
219 before investigating this, harmonization of neutralizing Ab titers is also necessary to
220 determine a common threshold from which vaccine protection could be predicted, allowing
221 then to find the corresponding threshold with high throughput binding Ab assays. A study

222 comparing different cell-based assays (with either live or pseudotyped viruses) to measure
223 neutralization in vitro is rather reassuring, although differences were found according to the
224 viruses used for pseudotyping (15). However, comparison of cell-based assays with surrogate
225 virus neutralization tests (sVNT) that are based on ELISA, and measuring the competition of
226 Ab and RBD for the binding to ACE, the cellular entry receptor of the virus, did not find good
227 agreement; this is inconvenient, as these assays could be promising given that they have
228 potential for large-scale.

229 In conclusion, the evaluated assays correlated well with each other but a difference in titers
230 remained after adjustment to the same International Standard. Thus, the titer harmonization is
231 not yet completely achieved, but it is better between assays detecting the same Ab against the
232 same antigen than between assays with different targets.

233

234 **Acknowledgements**

235 This study was supported by Hospices Civils de Lyon and Fondation des Hospices Civils de
236 Lyon. The respective suppliers kindly provided all the serological kits used in this study.

237 We thank all the staff members of the occupational health and medicine department of the
238 Hospices Civils de Lyon who contributed to the sample collection. We thank all Clinical
239 Research Associates, for their excellent work. We thank Karima Brahima and all the members
240 of the clinical research and innovation department for their reactivity (DRCI, Hospices Civils
241 de Lyon). Human biological samples and associated data were obtained from NeuroBioTec
242 (CRB HCL, Lyon France, Biobank BB-0033-00046). We thank all the technicians from the
243 virology laboratory of the Hospices Civils de Lyon who performed the assays on the
244 automated platforms. Lastly, we thank all the healthcare workers for their participation in this
245 clinical study, and Philip Robinson for critical reading of the manuscript and language
246 correction.

247

248 **References**

- 249 1. Shi A. C., Ren P. SARS-CoV-2 Serology Testing: Progress and Challenges. 2021. J
250 Immunol Methods 494 113060. <https://doi.org/10.1016/j.jim.2021.113060>
- 251 2. Bonelli F., Blocki F. A., Bunnell T., Chu E., De La O A., Grenache D. G., Marzucchi
252 G., Montomoli E., Okoye L., Pallavicini L., Strevia V. A., Torelli A., Wagner A., Zanin
253 D., Zierold C., Wassenberg J. J. Evaluation of the Automated LIAISON® SARS-CoV-
254 2 TrimericS IgG Assay for the Detection of Circulating Antibodies. 2021. Clin Chem
255 Lab Med 59 (8) 1463–1467. <https://doi.org/10.1515/ccim-2021-0023>.
- 256 3. Bradley B. T., Bryan A., Fink S. L., Goecker E. A., Roychoudhury P., Huang M.-L.,
257 Zhu H., Chaudhary A., Madarampalli B., Lu J. Y. C., Strand K., Whimbey E., Bryson-
258 Cahn C., Schippers A., Mani N. S., Pepper G., Jerome K. R., Morishima C., Coombs R.
259 W., Wener M., Cohen S., Greninger A. L. Anti-SARS-CoV-2 Antibody Levels
260 Measured by the Advise Dx SARS-CoV-2 Assay Are Concordant with Previously
261 Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity.
262 2021. J Clin Microbiol JCM0098921. <https://doi.org/10.1128/JCM.00989-21>.
- 263 4. English E., Cook L. E., Piec I., Dervisevic S., Fraser W. D., John W. G. Performance of
264 the Abbott SARS-CoV-2 IgG II Quantitative Antibody Assay Including the New
265 Variants of Concern (VOC 202012/V1 (UK) and VOC 202012/V2 (South Africa)):
266 And First Steps towards Global Harmonization of COVID-19 Antibody Methods.
267 2021. J Clin Microbiol JCM0028821 <https://doi.org/10.1128/JCM.00288-21>.
- 268 5. Irsara C., Egger A. E., Prokop W., Nairz M., Loacker L., Sahanic S., Pizzini A.,
269 Sonnweber T., Holzer B., Mayer W., Schennach H., Loeffler-Ragg J., Bellmann-Weiler
270 R., Hartmann B., Tancevski I., Weiss G., Binder C. J., Anliker M., Griesmacher A.,
271 Hoermann G. Clinical Validation of the Siemens Quantitative SARS-CoV-2 Spike IgG

- 272 Assay (SCOVG) Reveals Improved Sensitivity and a Good Correlation with Virus
273 Neutralization Titers. 2021. *Clin Chem Lab Med* 59 (8) 1453–1462.
274 <https://doi.org/10.1515/cclm-2021-0214>.
- 275 6. Narasimhan M., Mahimainathan L., Araj E., Clark A. E., Markantonis J., Green A., Xu
276 J., SoRelle J. A., Alexis C., Fankhauser K., Parikh H., Wilkinson K., Reczek A.,
277 Kopplin N., Yekkaluri S., Balani J., Thomas A., Singal A. G., Sarode R., Muthukumar
278 A. Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative
279 IgG and IgM Assays among Infected Recovered and Vaccinated Groups. 2021. *J Clin*
280 *Microbiol* 59 (7) e0038821. <https://doi.org/10.1128/JCM.00388-21>.
- 281 7. Perkmann T., Perkmann-Nagele N., Koller T., Mucher P., Radakovics A., Marculescu
282 R., Wolzt M., Wagner O. F., Binder C. J., Haslacher H. Anti-Spike Protein Assays to
283 Determine SARS-CoV-2 Antibody Levels: A Head-to-Head Comparison of Five
284 Quantitative Assays. 2021. *Microbiol Spectr* 9 (1) e0024721.
285 <https://doi.org/10.1128/Spectrum.00247-21>.
- 286 8. Addetia A., Crawford K. H. D., Dingens A., Zhu H., Roychoudhury P., Huang M.-L.,
287 Jerome K. R., Bloom J. D., Greninger A. L. Neutralizing Antibodies Correlate with
288 Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a
289 High Attack Rate. 2020. *J Clin Microbiol* 58 (11) e02107-20.
290 <https://doi.org/10.1128/JCM.02107-20>.
- 291 9. Letizia A. G., Ge Y., Vangeti S., Goforth C., Weir D. L., Kuzmina N. A., Balinsky C.
292 A., Chen H. W., Ewing D., Soares-Schanoski A., George M.-C., Graham W. D., Jones
293 F., Bharaj P., Lizewski R. A., Lizewski S. E., Marayag J., Marjanovic N., Miller C. M.,
294 Mofsowitz S., Nair V. D., Nunez E., Parent D. M., Porter C. K., Santa Ana E.,
295 Schilling M., Stadlbauer D., Sugiharto V. A., Termini M., Sun P., Tracy R. P.,
296 Krammer F., Bukreyev A., Ramos I., Sealfon S. C. SARS-CoV-2 Seropositivity and

- 297 Subsequent Infection Risk in Healthy Young Adults: A Prospective Cohort Study.
298 2021. *Lancet Respir Med* 9 (7) 712–720. [https://doi.org/10.1016/S2213-](https://doi.org/10.1016/S2213-2600(21)00158-2)
299 [2600\(21\)00158-2](https://doi.org/10.1016/S2213-2600(21)00158-2).
- 300 10. McMahan K., Yu J., Mercado N. B., Loos C., Tostanoski L. H., Chandrashekar A., Liu
301 J., Peter L., Atyeo C., Zhu A., Bondzie E. A., Dagotto G., Gebre M. S., Jacob-Dolan
302 C., Li Z., Nampanya F., Patel S., Pessaint L., Van Ry A., Blade K., Yalley-Ogunro J.,
303 Cabus M., Brown R., Cook A., Teow E., Andersen H., Lewis M. G., Lauffenburger D.
304 A., Alter G., Barouch D. H. Correlates of Protection against SARS-CoV-2 in Rhesus
305 Macaques. 2021. *Nature* 590 (7847) 630–634. [https://doi.org/10.1038/s41586-020-](https://doi.org/10.1038/s41586-020-03041-6)
306 [03041-6](https://doi.org/10.1038/s41586-020-03041-6).
- 307 11. Rogers T. F., Zhao F., Huang D., Beutler N., Burns A., He W., Limbo O., Smith C.,
308 Song G., Woehl J., Yang L., Abbott R. K., Callaghan S., Garcia E., Hurtado J., Parren
309 M., Peng L., Ramirez S., Ricketts J., Ricciardi M. J., Rawlings S. A., Wu N. C., Yuan
310 M., Smith D. M., Nemazee D., Teijaro J. R., Voss J. E., Wilson I. A., Andrabi R.,
311 Briney B., Landais E., Sok D., Jardine J. G., Burton D. R. Isolation of Potent SARS-
312 CoV-2 Neutralizing Antibodies and Protection from Disease in a Small Animal Model.
313 2020. *Science* 369 (6506) 956–963. <https://doi.org/10.1126/science.abc7520>.
- 314 12. Mattiuzzo G., Bentley E. M., Hassall M., Routley S., Bernasconi V., Kristiansen P.,
315 Harvala H., Roberts D., Semple G., Turtle L. C., Openshaw P. J., Baillie K.,
316 Investigators C., Nissen-Meyer L. S. H., Brants A. B., Atkinson E., Rigsby P., Padley
317 D., Almond N., Rose N. J., Page M. 2020. Establishment of the WHO International
318 Standard and Reference Panel for Anti-SARS-CoV-2 Antibody. WHO/BS/2020.2403.
319 <https://www.who.int/publications/m/item/WHO-BS-2020.2403>
- 320 13. Bal A., Pozzetto B., Trabaud M.-A., Escuret V., Rabilloud M., Langlois-Jacques C.,
321 Paul A., Guibert N., D'Aubarède-Frieh C., Massardier-Pilonchery A., Fabien N.,

- 322 Goncalves D., Boibieux A., Morfin-Sherpa F., Pitiot V., Gueyffier F., Lina B., Fassier
323 J.-B., Trouillet-Assant S., COVID SER Study Group. Evaluation of High-Throughput
324 SARS-CoV-2 Serological Assays in a Longitudinal Cohort of Patients with Mild
325 COVID-19: Clinical Sensitivity Specificity and Association with Virus Neutralization
326 Test. 2021. Clin Chem 67 (5) 742–752. <https://doi.org/10.1093/clinchem/hvaa336>.
- 327 14. Kristiansen P. A., Page M., Bernasconi V., Mattiuzzo G., Dull P., Makar K., Plotkin S.,
328 Knezevic I. WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin.
329 2021. The Lancet 397 (10282) 1347–1348. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(21)00527-4)
330 [6736\(21\)00527-4](https://doi.org/10.1016/S0140-6736(21)00527-4).
- 331 15. Sholukh A. M., Fiore-Gartland A., Ford E. S., Miner M. D., Hou Y. J., Tse L. V.,
332 Kaiser H., Zhu H., Lu J., Madarampalli B., Park A., Lempp F. A., St. Germain R.,
333 Bossard E. L., Kee J. J., Diem K., Stuart A. B., Rupert P. B., Brock C., Buerger M.,
334 Doll M. K., Randhawa A. K., Stamatatos L., Strong R. K., McLaughlin C., Huang M.-
335 L., Jerome K. R., Baric R. S., Montefiori D., Corey L. Evaluation of Cell-Based and
336 Surrogate SARS-CoV-2 Neutralization Assays. 2021. J Clin Microbiol. JCM0052721.
337 <https://doi.org/10.1128/JCM.00527-21>.
- 338
- 339

340 **TABLE 1:** Performance of 6 SARS-CoV-2 commercial serological assays.

341

Manufacturer	Wantai	Wantai	Siemens Healthineers	DiaSorin	bioMérieux	Abbott
platform			Atellica® IM	Liaison®	Vidas®	Architect
SARS-CoV-2 Detected Ab	Total Ab	IgG	IgG	IgG	IgG	IgG
Assay type	ELISA	ELISA	CLIA	CLIA	ELFA	CMIA
Antigen	RBD	RBD	RBD	Trimeric Spike	RBD	RBD
Positive threshold	Index = 1	U/mL = 0	U/mL = 1	AU/mL = 13	Index = 1	AU/mL = 50
Conversion factor (WHO standard)	N/A	N/A	21.8	2.6	20.33	0.142
Positive threshold (BAU/mL)	N/A	N/A	21.8	33.8	20.33	7.1
Positive samples, n (%)						
4 weeks after first injection	68 (86.1%)	79 (100%)	74 (93.6%)	76 (96.1%)	75 (94.9%)	66 (97.1%)
4 weeks after full vaccination	94 (100%)	94 (100%)	94 (100%)	94 (100%)	94 (100%)	9 (100%)

342

343

344

345

346 Positivity was established according to manufacturers' instructions.

347 Abbreviations: Ab: antibodies, Ig: immunoglobulin, ELISA: enzyme-linked immunosorbent

348 assay, CMIA: chemiluminescence microparticle immune assay CLIA: chemiluminescence

349 immune assay, ELFA: enzyme-linked fluorescent assay, N: number of samples, RBD:

350 Receptor Binding Domain, CI: confidence interval.

351

352

353

354

355

356 **FIG 1:** Comparison of anti SARS-CoV-2 antibodies concentration (BAU/mL) between all
357 assays in sera collected from vaccinated subjects. The statistical difference was evaluated by
358 Wilcoxon's test. A, Comparison of median titers (green) between Siemens, DiaSorin and
359 bioMérieux assays using 263 samples. B, Comparison of median titers (green) between
360 Siemens, DiaSorin, bioMérieux, and Abbott assays using 77 samples. BAU/mL: Binding
361 Antibodies Unit/mL. **** $p < 0.0001$. Data from patients scheduled to be vaccinated with 2
362 doses of Pfizer BioNtech vaccine (black) or with 1 dose of AstraZeneca vaccine followed by
363 1 dose of Pfizer BioNtech (blue) are presented.


364

365 **FIG 2:** Pearson correlation (ρ) between values obtained by all assays. A, Siemens compared
366 to DiaSorin assays with 263 samples ($p < 0.0001$). B, Siemens compared to bioMérieux assays
367 with 263 samples ($p < 0.0001$). C, DiaSorin compared to bioMérieux assays with 263 samples
368 ($p < 0.0001$). D, Siemens compared to Abbott assays with 77 samples ($p < 0.0001$). E, DiaSorin
369 compared to Abbott assays with 77 samples ($p < 0.0001$). F, bioMérieux compared to Abbott
370 assays with 77 samples ($p < 0.0001$). Data from patients scheduled to be vaccinated with 2
371 doses of Pfizer BioNtech vaccine (black) or with 1 dose of AstraZeneca vaccine followed by
372 1 dose of Pfizer BioNtech (blue) are presented.


373







374 **FIG 3:** Bland-Altman plots comparing agreement between concentrations determined using
375 the Siemens, DiaSorin, and bioMérieux assays. The solid blue line represents the bias
376 between assays, the dashed blue lines represent 95% limits of agreement.



A



B





A**B****C**